AFP Blood Test (Alpha-Fetoprotein): Normal Levels & High
The AFP (alpha-fetoprotein) blood test measures a tumor marker in ng/mL. Learn normal levels, what a high AFP means for liver and germ-cell cancer, and benign causes.
The AFP blood test measures alpha-fetoprotein, a protein your body makes in large amounts before birth and almost none of in adulthood. As a tumor marker, it is used mainly to help monitor liver cancer in people at risk and to diagnose and follow certain germ-cell tumors of the testicle or ovary. But here is the message that matters most: a high AFP is not a diagnosis of cancer. Alpha-fetoprotein rises for many benign reasons — chronic liver disease, hepatitis, cirrhosis, and pregnancy — and it is never read on its own. This guide explains what a normal AFP level looks like in ng/mL, what a high AFP does and does not mean, and why AFP is not a general cancer screening test. Like the PSA test, it is a signal to interpret in context, never a verdict on its own.
Key takeaways
- Alpha-fetoprotein is a fetal protein. In non-pregnant adults it stays low — most labs use a cutoff around < 10 ng/mL, but the exact value depends on the assay.12
- AFP is a tumor marker, not a cancer test: a high AFP does not confirm cancer, and a normal AFP does not rule it out.34
- Its two main uses are surveillance of hepatocellular carcinoma (HCC, liver cancer) in people at risk — always alongside a liver ultrasound — and the diagnosis and monitoring of germ-cell tumors of the testicle (and ovary).56
- A raised AFP most often comes from a benign liver condition: hepatitis, cirrhosis, or a regenerating liver. A mild elevation in that setting is frequently reassuring.78
- In pregnancy, AFP is naturally high — and the maternal serum AFP used in prenatal screening is a completely different test from the tumor marker.9
- What counts is the number, its trend over time, and the full clinical picture — not one isolated value. Interpretation belongs to your clinician.103
Normal AFP levels
These are general reference points for adults. The exact cutoff, unit, and method vary by laboratory, so always compare against the range printed on your report.
| Situation | Indicative reference value | Unit |
|---|---|---|
| Adult (non-pregnant) | usually < 10 (some labs < 7) | ng/mL |
| "Watch and recheck" zone | roughly 10 – 20 (repeat, put in context) | ng/mL |
| Pregnancy | physiologically high | ng/mL |
| Newborn / infant | very high, then falls with age | ng/mL |
Good to know: the usual unit is ng/mL (equivalent to µg/L; some labs report IU/mL, where 1 ng/mL ≈ 0.83 IU/mL). AFP is extremely high at birth and stays elevated for months, which makes results in babies hard to read.7 In adults, a value slightly above the cutoff that stays stable in a known liver condition is very different from one that is clearly high or rising.
What is alpha-fetoprotein?
Alpha-fetoprotein (AFP) is a protein made in large quantities by the fetal liver and yolk sac during pregnancy — essentially the fetus's version of albumin. After birth, production collapses, and blood levels in adults become very low.17 That is why a rise in AFP draws attention: some cells — whether tumor cells or a liver repairing itself — can switch AFP production back on, a kind of return to a "fetal" state.2
AFP is classed as a tumor marker: a substance measured in blood that can rise when certain cancers are present. But a tumor marker is not a diagnostic test. It points, monitors, and follows — it never decides on its own. A diagnosis always rests on imaging, sometimes a biopsy, and a specialist's judgment.35 The same caution applies to related markers such as CEA and CA-125.
Blood AFP is not the same as the pregnancy AFP test. This guide covers serum AFP as an adult tumor marker. AFP is also measured in prenatal screening during pregnancy (sometimes as part of a "triple" or "quad" screen for neural-tube defects) — a completely different use that is interpreted differently and is outside the scope of this page.9
What the AFP test is used for
Your clinician may order an AFP test to:
- monitor the liver in someone at risk of hepatocellular carcinoma — typically cirrhosis or chronic hepatitis B or C — as a complement to ultrasound;85
- help diagnose, stage, and monitor a germ-cell tumor of the testicle (or ovary), together with other markers such as beta-hCG and LDH;62
- track a treatment's effect or watch for recurrence when AFP was elevated to begin with — a fall during treatment is reassuring, a rise is a warning sign;6
- help work up a liver abnormality seen on imaging, alongside other tests.
AFP is not a mass-screening test for cancer in healthy people. Its place is targeted surveillance of at-risk groups and follow-up of known tumors.53 It is often drawn with a liver panel — markers like ALT and GGT — to give a fuller picture of liver health.
Interpreting your results
High AFP: think of the liver first — often benign
The most common cause of a mildly raised AFP is a benign liver condition: hepatitis (viral, alcohol-related, or other), cirrhosis, or a regenerating liver after injury. When liver cells repair themselves, they can start making AFP again — producing an elevation without any cancer.78 This is why a slightly high AFP in someone followed for hepatitis or cirrhosis is common and does not mean cancer: it is placed in context and rechecked.
Let's dismantle a myth: "high AFP equals liver cancer" is false. An elevation — especially a modest one — is most often benign. At the same time, the marker has real limits: many early liver cancers show a normal AFP. So a normal AFP is not reassuring on its own, and a high AFP does not confirm cancer. That is exactly why imaging is essential.43
Normal or low AFP
A normal or low AFP is the usual situation in a healthy adult. It does not guarantee the absence of a tumor (some cancers do not secrete AFP), but outside a specific clinical context it is a reassuring result. A low AFP is not a disease and needs no treatment.
What to do, and when to worry
It is not the isolated number that counts, but its level, its trend (stable? rising?), and the context (healthy or diseased liver, follow-up of a known tumor, pregnancy). A mildly raised, stable AFP in a known liver condition is often benign; an AFP that is clearly high, or that climbs from one check to the next, warrants medical review and imaging — explored step by step, without panic. The final interpretation belongs to your clinician.53
AFP is not a general cancer screening test
This is the honesty section, and it matters. AFP is not a screening test for the general population. Drawing it from a healthy person to "check for cancer" produces far more false alarms than answers.
Two facts explain why. First, AFP is not specific: it rises in chronic liver disease, hepatitis, cirrhosis, and pregnancy, so a high value on its own points nowhere in particular.37 Second, AFP is not sensitive enough: many early cancers, including early HCC, show a normal AFP, so a reassuring number can miss real disease.4 A test that both over-flags healthy people and misses early cancers cannot serve as a stand-alone screen.
That is why AFP is reserved for targeted surveillance in defined risk groups and for monitoring known tumors — always interpreted by a clinician with imaging and the whole picture. A high AFP is a reason to look closer, not a diagnosis.35
AFP in liver cancer surveillance
In people at higher risk of hepatocellular carcinoma — above all those with cirrhosis — the goal is to catch any cancer early. The reference strategy pairs a liver ultrasound with an AFP, usually every 6 months.85
AFP alone is not enough. Adding it to ultrasound improves early detection, but neither test is perfect. In a large meta-analysis, ultrasound alone detected only about 45% of early HCC, rising to roughly 63% when AFP was added.4 Hence the rule: AFP with ultrasound, at regular intervals — never AFP by itself.8
Guidelines have gone back and forth on how much weight to give AFP — some emphasize ultrasound with AFP as an adjunct, others treat its role more cautiously given imperfect sensitivity and specificity.54 The consistent thread: AFP is one input into surveillance, read with imaging and the patient's liver history — not a solo test.
AFP in testicular and germ cell tumors
AFP is a key marker for non-seminomatous germ-cell tumors of the testicle (and ovary), used alongside beta-hCG and LDH. Here it helps with diagnosis, staging, and — above all — monitoring: after surgery, the fall in AFP (following its half-life) reflects how well treatment is working, and a later rise can flag a recurrence.611
One useful distinction: pure seminomas do not produce AFP. So a high AFP in a testicular tumor points toward a non-seminomatous component, which can change how the cancer is classified and treated.6 As always, AFP is interpreted with the physical exam, scrotal ultrasound, and CT imaging — not in isolation.
What can raise AFP (benignly)
Several things move AFP that have nothing to do with a new cancer, and they should be flagged to your clinician:
- Liver conditions — hepatitis (viral or alcohol-related), cirrhosis, and a regenerating liver after injury are the most common benign causes of a raised AFP.78
- Pregnancy — AFP is physiologically high during pregnancy; this is normal and unrelated to the tumor marker.9
- Age — AFP is very high in newborns and declines over the first months of life, which makes results in infants hard to interpret.7
- The lab and units — the assay and the unit (ng/mL vs IU/mL) change how the number reads, so results are not always comparable between labs.2
Tell your clinician if you are pregnant, have known hepatitis, or are being followed for a liver condition — each of these changes how the result should be read.79
Recent research
According to recent PubMed publications and clinical-trial registries:
- Combined scores to detect liver cancer earlier. The GALAD score — which combines sex, age, and three blood markers (AFP, AFP-L3, and DCP) — detects hepatocellular carcinoma earlier than AFP alone. In a phase 3 validation study, its sensitivity reached about 62% a year before diagnosis, versus 41% for AFP at the same specificity.10 Other U.S. work confirms this sensitivity gain, but at the cost of more false positives, so the approach is still being evaluated.12 (Marsh TL et al., Gastroenterology, 2025; Tayob N et al., Clin Gastroenterol Hepatol, 2023.)
- Toward biomarker-based liver screening. A large randomized trial, the National Liver Cancer Screening Trial (TRACER, NCT06084234), compares standard ultrasound + AFP surveillance with a biomarker (GALAD) strategy in people with cirrhosis, to see which better reduces cancers found at a late stage.13
- Reading AFP in context, not against one cutoff. Recent reviews stress that AFP reference values vary widely with age, pregnancy, and liver disease — reinforcing that the result must always be interpreted in context rather than against a single threshold.7
These findings concern surveillance and monitoring; they do not authorize self-medication and do not replace your physician's advice.
Get your AFP interpreted by AI DiagMe
An AFP is never read alone: its meaning depends on your context (liver health, pregnancy, follow-up of a known tumor), its level, its trend over time, and other tests such as ultrasound and additional markers. A high AFP does not equal cancer.
👉 AI DiagMe interprets your lab results — blood, urine, or stool — in plain language, taking your whole profile into account. An informational service that does not provide a diagnosis and complements, never replaces, your physician.
Frequently asked questions
What is a normal AFP level?
What does a high AFP mean?
Is AFP a screening test for cancer?
What raises AFP besides cancer?
Is AFP the same as the pregnancy AFP test?
What AFP level is worrying?
Bottom line
The AFP blood test measures a fetal protein that is very low in adults and is used as a tumor marker — chiefly to monitor hepatocellular carcinoma (always with ultrasound) and to follow germ-cell tumors of the testicle and ovary. Remember the ballpark (< 10 ng/mL, lab-dependent), that pregnancy raises it normally, and above all that a high AFP is NOT a diagnosis of cancer: a modest rise is often benign (usually the liver), a normal AFP does not rule out a tumor, and a high AFP does not confirm one. It is the level, the trend, and the context — not the number alone — that guide, and interpretation belongs to your clinician. No value is read in isolation: it is your full set of markers and your profile that counts — like the neighboring liver markers ALT, GGT, and bilirubin — which is what AI DiagMe provides, alongside your physician.
Sources
Official sources and peer-reviewed publications (PubMed, ClinicalTrials.gov) used for this guide:
Footnotes
-
Adigun OO, Yarrarapu SNS, Zubair M, et al. Alpha-Fetoprotein Analysis. In: StatPearls. StatPearls Publishing, 2024. NCBI Bookshelf NBK430750 ↩ ↩2
-
Testing.com — Alpha-Fetoprotein (AFP) Tumor Marker Test. testing.com ↩ ↩2 ↩3 ↩4
-
National Cancer Institute (NIH) — Tumor Markers in Common Use. cancer.gov ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8
-
Tzartzeva K, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology, 2018. PubMed · DOI ↩ ↩2 ↩3 ↩4 ↩5
-
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 2018. PubMed · DOI ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8
-
Marshall C, et al. Serum tumor markers and testicular germ cell tumors: a primer for radiologists. Abdom Radiol (NY), 2019. PubMed · DOI ↩ ↩2 ↩3 ↩4 ↩5
-
Ferraro S, et al. Serum α-fetoprotein in pediatric oncology: not a children's tale. Clin Chem Lab Med, 2019. PubMed · DOI ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9
-
Marrero JA. Surveillance for Hepatocellular Carcinoma. Clin Liver Dis, 2020. PubMed · DOI ↩ ↩2 ↩3 ↩4 ↩5 ↩6
-
MedlinePlus (U.S. National Library of Medicine, NIH) — Alpha-fetoprotein (AFP) Tumor Marker Test. medlineplus.gov ↩ ↩2 ↩3 ↩4
-
Marsh TL, et al. A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis. Gastroenterology, 2025. PubMed · DOI ↩ ↩2
-
American Cancer Society — Tests for Testicular Cancer (blood tumor markers). cancer.org ↩
-
Tayob N, et al. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. Clin Gastroenterol Hepatol, 2023. PubMed · DOI ↩
-
ClinicalTrials.gov — National Liver Cancer Screening Trial (TRACER): ultrasound + AFP surveillance versus biomarkers (GALAD) in patients with cirrhosis. Identifier NCT06084234. clinicaltrials.gov ↩